Luis Puig

Luis Puig Esteve (April 9, 1915 – July 31, 1990) was a prominent Spanish sports executive known for his contributions to sports administration in the 20th century. Provided by Wikipedia
Showing 1 - 20 results of 22 for search 'Luis Puig', query time: 0.05s Refine Results
  1. 1
    Tyk2 Targeting in Immune-Mediated Inflammatory Diseases

    Tyk2 Targeting in Immune-Mediated Inflammatory Diseases by Lluís Rusiñol, Luis Puig

    Published 2023-02-01
    Get full text
    Article
  2. 2
    IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications

    IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications by Helena Iznardo, Luís Puig

    Published 2022-08-01
    Get full text
    Article
  3. 3
    Performances of students trained in algebraic problem solving in a spreadsheet environment and their relation to their competence in the Cartesian method

    Performances of students trained in algebraic problem solving in a spreadsheet environment and their relation to their competence in the Cartesian method by David Arnau, Luis Puig

    Published 2013-11-01
    Get full text
    Article
  4. 4
    Actuaciones de alumnos instruidos en la resolución algebraica de problemas en la hoja de cálculo y su relación con la competencia en el método cartesiano

    Actuaciones de alumnos instruidos en la resolución algebraica de problemas en la hoja de cálculo y su relación con la competencia en el método cartesiano by David Arnau, Luis Puig

    Published 2013-11-01
    Get full text
    Article
  5. 5
    Omnidirectional Structured Light in a Flexible Configuration

    Omnidirectional Structured Light in a Flexible Configuration by Luis Puig, Carmen Paniagua, José J. Guerrero

    Published 2013-10-01
    Get full text
    Article
  6. 6
    El estudio teórico local del desarrollo de competencias algebraicas

    El estudio teórico local del desarrollo de competencias algebraicas by Eugenio Filloy Yagüe, Luis Puig, Teresa Rojano

    Published 2009-06-01
    Get full text
    Article
  7. 7
    Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes

    Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque P... by Luís Puig, Martin Dossenbach, Lovisa Berggren, Anders Ljungberg, Claus Zachariae

    Published 2019-08-01
    Get full text
    Article
  8. 8
    Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study

    Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study by Luis Puig, José-Manuel Carrascosa, Esteban Daudén, Sara Sulleiro, Cristina Guisado

    Published 2020-05-01
    Get full text
    Article
  9. 9
    Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment

    Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment by Raquel Rivera-Díaz, Esteban Daudén, José Manuel Carrascosa, Pablo de la Cueva, Luis Puig

    Published 2023-01-01
    Get full text
    Article
  10. 10
    Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review

    Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review by Giampiero Girolomoni, Laura Savage, Paolo Gisondi, Åke Svensson, Emmanuel Mahé, Matthias Augustin, Luis Puig

    Published 2023-09-01
    Get full text
    Article
  11. 11
    Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2

    Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2 by Luis Puig, Jashin J. Wu, Melinda J. Gooderham, Yin You, Yaung-Kaung Shen, Bruce Randazzo, Francisco Kerdel

    Published 2021-07-01
    Get full text
    Article
  12. 12
    Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan

    Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan by Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, Ryuta Sakuma, Luis Puig, Matthew Davis, Dominic Nunag, Andreas Pinter, Shinichi Imafuku

    Published 2023-11-01
    Get full text
    Article
  13. 13
    Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial

    Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial by April Armstrong, Luis Puig, Richard Langley, Tsen Fang Tsai, Michael Song, Yasmine Wasfi, Jingzhi Jiang, Shu Li, Chenglong Han

    Published 2019-01-01
    Get full text
    Article
  14. 14
    PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries

    PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries by Anna Langenbruch, Nicole Mohr, Valerie Andrees, Ihno Kessens, Adam Reich, Magdalena Czarnecka-Operacz, Luis Puig, Esteban Dauden, Lars Iversen, Matthias Augustin

    Published 2023-08-01
    Get full text
    Article
  15. 15
    Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks

    Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks by Alexander Egeberg, Lars Erik Kristensen, Luis Puig, Phoebe Rich, Saxon D. Smith, Alyssa Garrelts, Kyoungah See, Thorsten Holzkaemper, Konstantinos Fotiou, Christopher Schuster

    Published 2023-12-01
    Get full text
    Article
  16. 16
    Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

    Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis by Kristian Reich, Curdin Conrad, Lars Erik Kristensen, Saxon D. Smith, Luis Puig, Phoebe Rich, Christophe Sapin, Thorsten Holzkaemper, Uffe Koppelhus, Christopher Schuster

    Published 2022-04-01
    Get full text
    Article
  17. 17
    A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis

    A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis by Bruce W. Kirkham, Alexander Egeberg, Frank Behrens, Andreas Pinter, Joseph F. Merola, Thorsten Holzkämper, Gaia Gallo, Khai Jing Ng, Rebecca Bolce, Christopher Schuster, Peter Nash, Luis Puig

    Published 2023-07-01
    Get full text
    Article
  18. 18
    Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial

    Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo... by Luis Puig, Andrey L. Bakulev, Muza M. Kokhan, Alexey V. Samtsov, Vladislav R. Khairutdinov, Maria A. Morozova, Nikita A. Zolkin, Ivan V. Kuryshev, Alexey N. Petrov, Antonina V. Artemeva, Arina V. Zinkina-Orikhan

    Published 2021-10-01
    Get full text
    Article
  19. 19
    Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

    Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: a... by Michael J. Cork, Laurent Eckert, Eric L. Simpson, April Armstrong, Sébastien Barbarot, Luis Puig, Giampiero Girolomoni, Marjolein de Bruin-Weller, Andreas Wollenberg, Yoko Kataoka, Anita Remitz, Stefan Beissert, Vera Mastey, Marius Ardeleanu, Zhen Chen, Abhijit Gadkari, Jingdong Chao

    Published 2020-08-01
    Get full text
    Article
  20. 20
    The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases

    The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases by Victoria Navarro-Compán, Luis Puig, Silvia Vidal, Julio Ramírez, Mar Llamas-Velasco, Cristina Fernández-Carballido, Raquel Almodóvar, José Antonio Pinto, Eva Galíndez-Aguirregoikoa, Pedro Zarco, Beatriz Joven, Jordi Gratacós, Xavier Juanola, Ricardo Blanco, Salvador Arias-Santiago, Salvador Arias-Santiago, Salvador Arias-Santiago, Jesús Sanz Sanz, Rubén Queiro, Juan D. Cañete

    Published 2023-08-01
    Get full text
    Article

Search Tools: